NCT00059904已完成2 期
An Open-Labeled, Phase II Study of Rituximab in Combination With Recombinant IL-2 for Relapsed or Refractory Non-Hodgkin's Lymphoma of Intermediate- or High-Grade Histology
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-2 may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining rituximab with interleukin-2 in treating patients who have relapsed or refractory intermediate- or high-grade non-Hodgkin's lymphoma.
详细描述
OBJECTIVES:
- Determine the clinical efficacy of rituximab and interleukin-2 in patients with relapsed or refractory intermediate- or high-grade non-Hodgkin's lymphoma.
- Determine the 2-year progression-free survival of patients treated with this regimen.
- Determine the safety of this regimen in these patients.
- Correlate response with natural killer cell numbers and rituximab, interleukin-2 (IL-2), and soluble IL-2 receptor levels in patients treated with this regimen.
OUTLINE: This is an open-label, multicenter study.
Patients receive rituximab IV once weekly on weeks 1-4 and interleukin-2 subcutaneously 3 times weekly on weeks 2-9. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 12 weeks for 2 years.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Diagnosis of intermediate- or high-grade non-Hodgkin's lymphoma according to the Working Formulation, including the following subtypes:
- •Diffuse large cell lymphoma
- •Diffuse mixed cell lymphoma
- •Immunoblastic large cell lymphoma
- •CD20+ disease
- •Measurable progressive or refractory disease
- •No primary CNS lymphoma or lymphomatous meningitis NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Lymphocyte count less than 20,000/mm^3
- •Absolute neutrophil count at least 1,000/mm^3
- •Platelet count at least 75,000/mm^3
- •Hemoglobin at least 9.5 g/dL
- •SGOT and SGPT no greater than 1.5 times upper limit of normal
- •Bilirubin normal
- •No liver disease
- •Hepatitis C-seropositive patients are allowed provided they have no active disease, as demonstrated by any of the following:
- •Undetectable hepatitis C viral loads
- •Biopsy showing no active disease
- •Normal transaminases on at least 3 different occasions within the past year
- •Creatinine normal
- •Cardiovascular
- •No clinically significant cardiac dysfunction
- •No myocardial infarction within the past 6 months
- •No heart failure within the past 6 months
- •No clinically significant pulmonary dysfunction
- •Patients with prior radiotherapy to the lung or autologous transplantation must have FEV greater than 50% and DLCO greater than 50% within 8 weeks before study treatment
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •HIV negative
- •No significant infections within the past 2 weeks (including pneumonia or bronchitis)
- •No history of autoimmune disease
- •No prior or concurrent malignancy except inactive nonmelanoma skin cancer, carcinoma in situ of the cervix, or other solid tumor curatively treated with no evidence of recurrence within the past 2 years
- •No symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism
- •No prior type 1 hypersensitivity or anaphylactic reactions to murine products, rituximab, or radioimmunoconjugated anti-CD20 antibody infusion
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •At least 3 months since prior autologous bone marrow transplantation
- •No prior allogeneic bone marrow transplantation
- •No prior interleukin-2
- •No prior interferon (alfa, beta, or gamma)
- •No concurrent basiliximab, daclizumab, or monoclonal antibody OKT3
- •Chemotherapy
- •More than 30 days since prior chemotherapy
- 另有 15 项未显示
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaLymphomaNCT00005959Amgen
终止
2 期
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's MacroglobulinemiaLymphomaNCT00060346Eastern Cooperative Oncology Group16
已完成
1 期
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaLymphomaNCT00040950Jonsson Comprehensive Cancer Center
已完成
2 期
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's LeukemiaLymphomaLeukemiaNCT00039130Alliance for Clinical Trials in Oncology105
已完成
2 期
Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's LymphomaLymphomaNCT00071955Genitope Corporation